uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted July 06, 2021

CBD Products Were Promoted to Treat Cancer and Alzheimer's Without Proof, Says FTC

On July 6, 2021, the Federal Trade Commission (FTC) announced that it has approved a final administrative consent orders against Kushly Industries LLC and the company's owner, Cody Alt, for allegedly making unsupported health claims about its CBD products.

According to the FTC's complaint, the company made false claims that Kushly CBD products could treat or cure serious conditions such as cancer, multiple sclerosis, Parkinson's disease, and Alzheimer's disease, as well as hypertension, psoriasis and acne.

(See ConsumerLab's answers to the questions Do supplements help with Parkinson's disease treatment or prevention? and Do any supplements reduce multiple sclerosis symptoms or relapse?)

The final order requires Kushly to pay $30,583.14 (the amount consumers paid the company for the falsely promoted products), and bans the company from making unsubstantiated claims about its products.

Consumers are encouraged to report scams, fraud, and bad business practices at

See ConsumerLab's Review of CBD & Hemp Extract Supplements, Lotions, and Balms for tests of related products.

For more information, use the link below.

FTC Approves Final Administrative Consent Order against Kushly Industries LLC and its Owner for Making Unsupported Health Claims for CBD Products

See related recalls and warnings:

FTC Takes Further Action Against Deceptive CBD Claims

FTC Crackdown on Six Deceptive CBD Products

FDA Warns Sellers of Unapproved COVID-19 Tests, CBD Products

Seller of CBD and NAC Warned for Coronavirus Claims

51 CBD Products Recalled Due to Lead Contamination

Seller of CBD Tinctures and "Immune Boost Packs" Warned for Coronavirus Claims